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96and plaque destabilizing apoptosis of intimal macro-
phages and smooth muscle cells. Indeed, both
4-phenylbutyrate and taurodeoxycholate are re-
ported to exert antiatherosclerotic activity in rodent
studies and to suppress induction of CD36 and
scavenger receptor A in macrophages. In notable
contrast, TMAO has been found to have a proa-
therogenic effect in mice and to up-regulate CD36
and scavenger receptor A expression in macrophages
(5). Although it is quite conceivable that TMAO has
some idiosyncratic adverse countervailing effect
on foam cells that outweighs the beneﬁt of its
inhibitory inﬂuence on ER stress, it should be noted
that only 1 research group to date has reported a
proatherogenic role for TMAO; this observation
needs independent conﬁrmation before it can be
accepted as established fact.*Mark F. McCarty, BA
James J. DiNicolantonio, PharmD
*Catalytic Longevity
7831 Rush Rose Drive
Apt. 316
Carlsbad, California 92009
E-mail: markfmccarty@gmail.com
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We thank Mr. McCarty and Dr. DiNicolantonio for
their interest and their opinions regarding our dis-
covery of a previously unappreciated role for the
potential involvement of a speciﬁc gut microbiota–
dependent pathway leading to higher circulating
trimethylamine N-oxide (TMAO) levels that wereassociated with a worse prognosis independent of
traditional cardiorenal indices and risk factors. We
believe that the observed associations are hypothesis
generating and call for further rigorous mechanistic
investigations. Our reported association between
elevated TMAO levels and an adverse prognosis
among subjects with heart failure was recently vali-
dated in independent cohorts of patients, including
among subjects with chronic systolic heart failure
(left ventricular ejection fraction #35%) with well-
characterized echocardiographic assessments (1),
as well as in a Norwegian cohort with similar
observations (2). There are also emerging data to
demonstrate the potential interplay between TMAO
and other neurohormonal systems that are implicated
in the pathogenesis of heart failure and other car-
diovascular diseases (3). Thus, a rapidly growing body
of evidence suggests that elevated TMAO levels are
strikingly linked to an adverse prognosis in heart
failure patients, and further studies are warranted to
determine whether the observed associations are
causal, which may point toward important potential
nutritional or other preventive efforts that might
mitigate the observed risk.
We agree that the role of dietary choices and
nutritional exposure as mechanistic underpinnings
of heart failure pathophysiology has been specu-
lated for several decades. However, unlike many
commentaries, we are very careful not to make any
unfounded speculations regarding any single di-
etary source of TMAO production as the sole culprit.
The challenge in investigations of this topic is
largely due to the difﬁculties in objective quanti-
ﬁcation in a rigorous scientiﬁc manner. Epidemio-
logical studies are limited in their precision and
accuracy to measure dietary composition. In our
own published data, systemic levels of L-carnitine,
choline, as well as betaine portend poorer long-term
prognosis when there is a concomitant increase in
circulating TMAO levels. Moreover, we recently
discovered the contributory role of g-butyrobetaine,
an intermediate metabolite of L-carnitine that is
vital to carnitine metabolism in vegetarians/vegans,
which may potentially siphon oral L-carnitine avail-
ability upstream from the gastrointestinal tract (4).
These novel observations further illustrate the
complex interplay between dietary nutrients, gut
microbial metabolism, and host homeostasis, above
and beyond a simplistic explanation to justify or
refute any therapeutic approaches. It is true that
some species of ﬁsh have a high TMAO content,
whereas many others do not. A similar situation is
observed with the content of speciﬁc molecular
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very little.
The issue regarding L-carnitine supplementation
itself being beneﬁcial in the setting of chronic heart
failure is far from being substantiated scientiﬁcally.
Indeed, we ﬁnd the characterization and analyses of
Mr. McCarty and Dr. DiNicolantonio quite misleading.
Although there may be short-term myocardial effects
and theoretical beneﬁts, the majority of human
studies in this area were performed more than 2
decades ago and predominantly in the acute post-
infarction setting (4). Careful review of L-carnitine
supplementation studies in chronic heart failure
revealed that all were short of duration and in
patients not even receiving contemporary therapies
(such as angiotensin-converting enzyme inhibitors
and beta-blockers) (4). The study that was quoted as
demonstrating the beneﬁts of L-carnitine included 80
subjects not taking beta-blockers (with open-label L-
carnitine use after 3 months) and reported 7 deaths in
3 years of follow-up (annualized mortality rate of
3.3%, surprisingly low for a population in New York
Heart Association functional class III to IV). Results
from Dr. DiNicolantonio’s own meta-analysis actually
did not demonstrate any signiﬁcant effects on car-
dioprotection as it relates to preventing reinfarction
(p ¼ 0.45) or future development of heart failure
(p ¼ 0.21) with L-carnitine supplementation (4). When
the studies with <10 events were excluded, no ben-
eﬁts were apparent, and the evidence is therefore
largely inconsistent (4). What this particular meta-
analysis also failed to emphasize is that during the
6-month follow-up of the largest randomized study
performed by Tarantini et al. (n ¼ 2,330), the primary
endpoint (all-cause mortality and heart failure) was
not signiﬁcantly different in the L-carnitine and pla-
cebo groups (p ¼ 0.27) (5). In fact, there were
numerically more mortality events observed after the
ﬁrst 5 days of enrollment post-infarction in the
L-carnitine–treated group compared with placebo at
180 days (40/1,141 [3.5%] vs. 31/1,117 [2.8%]) (5). This
is the fundamental challenge of claiming therapeutic
effects by statistical means without examining or
appreciating the primary data source or validating
mechanistic evidence. It would be important to ﬁrst
distinguish scientiﬁc evidence from testimonial be-
liefs and objectively examine and report what the
data actually showed.
Although interventions that targeted metabolic
modulation have been tried over several decades
based on our understanding of the importance of
impaired energetics of the failing heart, few thera-
peutic interventions, if any, reached the threshold ofindependent validation. It is not surprising that the
latest American College of Cardiology/American
Heart Association guidelines systematically re-
viewed the current evidence and do not recom-
mend the use of otherwise unregulated nutritional
supplements, including carnitine, in the treatment
of chronic heart failure with systolic dysfunction
due to lack of beneﬁt. We believe that the growing
body of data demonstrating mechanistic links be-
tween the gut microbiota–dependent TMAO pathway
and both atherosclerosis and renal functional
impairment in animal models, coupled with the in-
dependent clinical studies now reporting strong as-
sociations between elevated TMAO levels and
adverse prognosis are a call for concern. The po-
tential long-term adverse risk of high-dose, long-
term L-carnitine supplementation as nutritional
intervention simply cannot be overlooked and re-
quires further investigation. In our humble opinion,
the cardioprotective beneﬁts are not ﬁrmly estab-
lished, yet the risks are foreseeable and quantiﬁable
in some individuals.*W.H. Wilson Tang, MD
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